Navigation path

Pharmaceuticals - Community Register


List of refusals for human medicinal products

Natalizumab Elan Pharma

Product name: Natalizumab Elan Pharma
Active substance: Natalizumab
Indication: Treatment of moderate to severe active Crohn’s disease in patients who had an inadequate response to or could not take conventional treatments for the disease and who have evidence of active inflammation.
Marketing Authorisation Holder: Elan Pharma Ltd

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
15/01/2008 Centralised - Refusal of marketing authorisation EMEA/H/C/624 (2008)154 of 11/01/2008